Abstract
Transcription factors play essential roles in controlling normal blood development and their alteration leads to abnormalities in cell proliferation, differentiation and survival. In many childhood acute leukemias, transcription factors are altered through chromosomal translocations that change their functional properties resulting in repressed activity or inappropriate activation. The development of therapies that specifically target these molecular abnormalities holds promise for improving the outcome in diseases that remain challenging to treat, such as childhood T-cell acute lymphoblastic leukemia and acute myeloid leukemia, with improved toxicity profiles. All trans-retinoic acid and arsenic trioxide have already demonstrated efficacy in acute promyelocytic leukemia in both adults and children. Newer agents, such as histone deacetylase inhibitors, drugs targeting the NOTCH pathway, and short interfering RNAs have shown encouraging results in pre-clinical studies and are likely to enter the clinical arena in the near future. Through an improved understanding of the pathways and mechanisms underlying the malignant transformation induced by altered transcription factors, new targeted therapies will be designed that should greatly enhance current available treatments.
Keywords: Transcription factors, ALL, AML, promyelocytic leukemia, HDAC inhibitors, all-trans retinoic acid (ATRA), targeted therapy, NOTCH
Current Drug Targets
Title: Targeting Transcription Factors in Acute Leukemia in Children
Volume: 8 Issue: 6
Author(s): Jason N. Berman and A. Thomas Look
Affiliation:
Keywords: Transcription factors, ALL, AML, promyelocytic leukemia, HDAC inhibitors, all-trans retinoic acid (ATRA), targeted therapy, NOTCH
Abstract: Transcription factors play essential roles in controlling normal blood development and their alteration leads to abnormalities in cell proliferation, differentiation and survival. In many childhood acute leukemias, transcription factors are altered through chromosomal translocations that change their functional properties resulting in repressed activity or inappropriate activation. The development of therapies that specifically target these molecular abnormalities holds promise for improving the outcome in diseases that remain challenging to treat, such as childhood T-cell acute lymphoblastic leukemia and acute myeloid leukemia, with improved toxicity profiles. All trans-retinoic acid and arsenic trioxide have already demonstrated efficacy in acute promyelocytic leukemia in both adults and children. Newer agents, such as histone deacetylase inhibitors, drugs targeting the NOTCH pathway, and short interfering RNAs have shown encouraging results in pre-clinical studies and are likely to enter the clinical arena in the near future. Through an improved understanding of the pathways and mechanisms underlying the malignant transformation induced by altered transcription factors, new targeted therapies will be designed that should greatly enhance current available treatments.
Export Options
About this article
Cite this article as:
Berman N. Jason and Thomas Look A., Targeting Transcription Factors in Acute Leukemia in Children, Current Drug Targets 2007; 8 (6) . https://dx.doi.org/10.2174/138945007780830818
DOI https://dx.doi.org/10.2174/138945007780830818 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab
Current Medicinal Chemistry Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor
Current Topics in Medicinal Chemistry The LPS-Pretreated MSCs Supply a Positive Microenvironment for Tumor Cell Proliferation and Clone Formation
Current Protein & Peptide Science Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Dissecting the Therapeutic Potency of Antimicrobial Peptides Against Microbial Biofilms
Current Protein & Peptide Science Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry Viruses and Oral Cancer: Crossreactivity as a Potential Link
Anti-Cancer Agents in Medicinal Chemistry A Phase I Study of OMN54 (Aneustat™) in Patients with Advanced Malignancies
Clinical Cancer Drugs Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer
Current Gene Therapy MicroRNAs: Regulators of TLR2-Mediated Probiotic Immune Responses
MicroRNA Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Overview: Translating Hsp90 Biology into Hsp90 Drugs
Current Cancer Drug Targets Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
Cardiovascular & Hematological Agents in Medicinal Chemistry The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets Organic Fluorescent Dye-based Nanomaterials: Advances in the Rational Design for Imaging and Sensing Applications
Current Medicinal Chemistry Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Evaluation of Micro-RNA Levels, Apoptosis and Oxidative Stress Markers in Patients Recieving Chemotherapy
Combinatorial Chemistry & High Throughput Screening